Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study.
Hepatocellular carcinoma
Radiotherapy dosage
Stereotactic body radiotherapy
Survival rate
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
21 Apr 2021
21 Apr 2021
Historique:
received:
30
12
2020
accepted:
01
03
2021
entrez:
22
4
2021
pubmed:
23
4
2021
medline:
30
11
2021
Statut:
epublish
Résumé
The optimal dose and fractionation scheme of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) remains unclear due to different tolerated liver volumes and degrees of cirrhosis. In this study, we aimed to verify the dose-survival relationship to optimize dose selection for treatment of HCC. This multicenter retrospective study included 602 patients with HCC, treated with SBRT between January 2011 and March 2017. The SBRT dosage was classified into high dose, moderate dose, and low dose levels: SaRT (BED The median tumor size was 5.6 cm (interquartile range [IQR] 1.1-21.0 cm). The median follow-up time was 50.0 months (IQR 6-100 months). High radiotherapy dose correlated with better outcomes. After classifying into the SaRT, SbRT, and ScRT groups, three notably different curves were obtained for long-term post-SBRT survival and intrahepatic control. On multivariate analysis, higher radiation dose was associated with improved OS, PFS, and intrahepatic control. If tolerated by normal tissue, we recommend SaRT (BED
Sections du résumé
BACKGROUND
BACKGROUND
The optimal dose and fractionation scheme of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) remains unclear due to different tolerated liver volumes and degrees of cirrhosis. In this study, we aimed to verify the dose-survival relationship to optimize dose selection for treatment of HCC.
METHODS
METHODS
This multicenter retrospective study included 602 patients with HCC, treated with SBRT between January 2011 and March 2017. The SBRT dosage was classified into high dose, moderate dose, and low dose levels: SaRT (BED
RESULTS
RESULTS
The median tumor size was 5.6 cm (interquartile range [IQR] 1.1-21.0 cm). The median follow-up time was 50.0 months (IQR 6-100 months). High radiotherapy dose correlated with better outcomes. After classifying into the SaRT, SbRT, and ScRT groups, three notably different curves were obtained for long-term post-SBRT survival and intrahepatic control. On multivariate analysis, higher radiation dose was associated with improved OS, PFS, and intrahepatic control.
CONCLUSIONS
CONCLUSIONS
If tolerated by normal tissue, we recommend SaRT (BED
Identifiants
pubmed: 33882972
doi: 10.1186/s13014-021-01778-6
pii: 10.1186/s13014-021-01778-6
pmc: PMC8058965
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
79Subventions
Organisme : National Natural Science Foundation of China
ID : 81903257
Organisme : National Natural Science Foundation of China
ID : 81960534
Organisme : Natural Science Foundation of Guangxi Province (CN)
ID : 2020JJA140141
Organisme : China International Medical Foundation-Tumor Precise Radiotherapy Spark Program
ID : 2019-N-11-01
Organisme : National Major Science and Technology Projects of China (CN)
ID : 2017ZX10203207
Références
Front Oncol. 2020 Mar 24;10:347
pubmed: 32266136
Hepatol Int. 2020 Sep;14(5):788-797
pubmed: 32886334
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Radiat Oncol. 2013 Oct 27;8:250
pubmed: 24160944
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
J Natl Compr Canc Netw. 2017 May;15(5):563-573
pubmed: 28476736
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):116-125
pubmed: 32001057
Radiother Oncol. 2014 Mar;110(3):499-504
pubmed: 24630539
Radiat Oncol. 2019 Mar 27;14(1):50
pubmed: 30917853
Onco Targets Ther. 2017 Nov 06;10:5289-5295
pubmed: 29158680
Radiother Oncol. 2015 May;115(2):211-6
pubmed: 26028227
J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100
pubmed: 17603311
BMC Cancer. 2019 Aug 28;19(1):846
pubmed: 31455251
Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):344-50
pubmed: 25636759
J Clin Oncol. 2016 Feb 10;34(5):452-9
pubmed: 26628466
Cancer. 2016 Jul 1;122(13):2041-9
pubmed: 27062278
Clin Mol Hepatol. 2020 Oct;26(4):506-515
pubmed: 32646200
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):639-646
pubmed: 28581406
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):122-130
pubmed: 29066120
BMC Cancer. 2016 Nov 3;16(1):834
pubmed: 27809890
Acta Oncol. 2014 Mar;53(3):399-404
pubmed: 23962244
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Liver Cancer. 2018 Sep;7(3):235-260
pubmed: 30319983
J Clin Oncol. 2018 Feb 20;36(6):600-608
pubmed: 29328861
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
PLoS One. 2013 Oct 11;8(10):e77472
pubmed: 24147002
J Clin Oncol. 2018 Aug 20;36(24):2566-2567
pubmed: 29945529
J Surg Oncol. 2016 Feb;113(2):181-7
pubmed: 26799260
Radiother Oncol. 2018 Oct;129(1):136-142
pubmed: 29548558
J Cancer Res Clin Oncol. 2015 Jul;141(7):1301-9
pubmed: 25644863
Front Oncol. 2020 Jul 31;10:1205
pubmed: 32850352